CFTR Modulators Correct Trafficking Defects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis and other diseases associated with defective protein trafficking, such as CFTR, are limited in efficacy and specificity, particularly for mutations like ΔF508-CFTR that lead to misfolding and ER processing defects, resulting in reduced anion transport and severe disease symptoms.
Innovation Solution
Development of compounds that modulate ABC transporter activity, specifically targeting CFTR to enhance anion secretion and correct trafficking defects, thereby treating a range of diseases including cystic fibrosis, COPD, dry eye disease, and Sjögren's syndrome by increasing anion transport across epithelial membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatments are used for cystic fibrosis, then current standard of care is maintained, but efficacy and specificity are limited
Solution Approach 1:
The patent modifies the chemical structure of CFTR modulators by changing parameters such as the R1-R4 substituents and k value in the general formula, creating compounds with improved efficacy and specificity for different CFTR mutations including ΔF508-CFTR
Solution Approach 2:
The invention introduces specific local chemical features at different positions (R1, R2, R3, R4) of the CFTR modulator molecule to target specific mutation types and cellular processes, enabling differentiated treatment effects for various cystic fibrosis presentations
2Productivity
If CFTR activity is increased to improve anion transport, then anion secretion is enhanced, but trafficking defects may be exacerbated
Solution Approach 1:
The patent creates dynamic modulation of CFTR activity through compounds that can adaptively regulate both anion transport and trafficking processes, allowing the system to optimize function while maintaining stability through the flexible chemical structure parameters
Solution Approach 2:
The CFTR modulators described provide feedback control by monitoring and regulating CFTR channel activity and trafficking simultaneously, preventing over-activation while ensuring sufficient anion transport through the coordinated action of the molecular structure
3Adaptability or versatility
If broad-spectrum treatments are used, then multiple diseases are addressed, but manufacturing precision and specificity are reduced
Solution Approach 1:
The patent develops a universal CFTR modulator platform with a general formula that can treat multiple diseases (cystic fibrosis, COPD, dry eye disease, Sjögren's syndrome) by adjusting the R1-R4 and k parameters, achieving both broad disease coverage and precise molecular targeting
Solution Approach 2:
The invention segments the CFTR modulator structure into distinct functional regions (R1, R2, R3, R4 substituents) that can be independently optimized for different disease indications while maintaining the core molecular framework, enabling precise control over therapeutic specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively modulate CFTR activity to improve anion secretion, correct trafficking defects, and alleviate symptoms in various diseases by enhancing fluid transport and mucociliary clearance, offering a broader therapeutic approach beyond traditional treatments.
Implementation Method 1
CFTR is the cAMP/ATP-mediated anion channel... regulates anion flux across the membrane... increasing anion transport across epithelia
Data Source
AI summary
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.